Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
Hanania NA, Castro M, Bateman E, Pavord ID, Papi A, FitzGerald JM, Maspero JF, Katelaris CH, Singh D, Daizadeh N, Altincatal A, Pandit-Abid N, Soler X, Siddiqui S, Laws E, Jacob-Nara JA, Rowe PJ, Lederer DJ, Hardin M, Deniz Y. Hanania NA, et al. Among authors: altincatal a. Ann Allergy Asthma Immunol. 2023 Feb;130(2):206-214.e2. doi: 10.1016/j.anai.2022.10.018. Epub 2022 Nov 2. Ann Allergy Asthma Immunol. 2023. PMID: 36332763 Free article. Clinical Trial.
Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.
Berger P, Menzies-Gow A, Peters AT, Kuna P, Rabe KF, Altincatal A, Soler X, Pandit-Abid N, Siddiqui S, Jacob-Nara JA, Deniz Y, Rowe PJ. Berger P, et al. Among authors: altincatal a. Ann Allergy Asthma Immunol. 2023 Feb;130(2):215-224. doi: 10.1016/j.anai.2022.11.006. Epub 2022 Nov 7. Ann Allergy Asthma Immunol. 2023. PMID: 36356712 Free article. Clinical Trial.
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.
Corren J, Jackson DJ, Casale TB, Borish L, Rabe KF, Busse WW, Maspero JF, Jackson DJ, Daizadeh N, Altincatal A, Radwan A, Khodzhayev A, Djandji M, Jacob-Nara JA, Rowe PJ, Deniz Y. Corren J, et al. Among authors: altincatal a. J Asthma Allergy. 2023 Mar 7;16:249-260. doi: 10.2147/JAA.S385645. eCollection 2023. J Asthma Allergy. 2023. PMID: 36915284 Free PMC article.
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
Corren J, Katelaris CH, Castro M, Maspero JF, Humbert M, Halpin DMG, Altincatal A, Pandit-Abid N, Soler X, Radwan A, Jacob-Nara JA, Deniz Y, Rowe PJ. Corren J, et al. Among authors: altincatal a. ERJ Open Res. 2023 Oct 16;9(5):00037-2023. doi: 10.1183/23120541.00037-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37859672 Free PMC article.
Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study.
Bacharier LB, Guilbert TW, Katelaris CH, Deschildre A, Phipatanakul W, Liu D, Altincatal A, Mannent LP, Amin N, Laws E, Akinlade B, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M. Bacharier LB, et al. Among authors: altincatal a. J Allergy Clin Immunol Pract. 2024 Apr;12(4):948-959. doi: 10.1016/j.jaip.2023.12.006. Epub 2023 Dec 11. J Allergy Clin Immunol Pract. 2024. PMID: 38092225 Free article. Clinical Trial.
46 results